News

Filter results
E.g., 22/04/2024
E.g., 22/04/2024
02/04/2024
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults
12/03/2024
This public-private collaboration instrument falls within the framework of the Vanguard Health Strategic Project for Economic Recovery and Transformation (PERTE) and will have an initial investment of over 74 million euros
27/02/2024
ROVI achieved operating revenue growth of 1% in the first post-pandemic year